Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Nov;31(11):3161-78.
doi: 10.1007/s11095-014-1409-0. Epub 2014 Jun 7.

Concentration dependent viscosity of monoclonal antibody solutions: explaining experimental behavior in terms of molecular properties

Affiliations

Concentration dependent viscosity of monoclonal antibody solutions: explaining experimental behavior in terms of molecular properties

Li Li et al. Pharm Res. 2014 Nov.

Abstract

Purpose: Early identification of monoclonal antibody candidates whose development, as high concentration (≥100 mg/mL) drug products, could prove challenging, due to high viscosity, can help define strategies for candidate engineering and selection.

Methods: Concentration dependent viscosities of 11 proprietary mAbs were measured. Sequence and structural features of the variable (Fv) regions were analyzed to understand viscosity behavior of the mAbs. Coarse-grained molecular simulations of two problematic mAbs were compared with that of a well behaved mAb.

Results: Net charge, ξ-potential and pI of Fv regions were found to correlate with viscosities of highly concentrated antibody solutions. Negative net charges on the Fv regions of two mAbs with poor viscosity behaviors facilitate attractive self-associations, causing them to diffuse slower than a well-behaved mAb with positive net charge on its Fv region. An empirically derived equation that connects aggregation propensity and pI of the Fv region with high concentration viscosity of the whole mAb was developed.

Conclusions: An Fv region-based qualitative screening profile was devised to flag mAb candidates whose development, as high concentration drug products, could prove challenging. This screen can facilitate developability risk assessment and mitigation strategies for antibody based therapeutics via rapid high throughput material-free screening.

PubMed Disclaimer

References

    1. Biotechnol J. 2012 Dec;7(12):1444-50 - PubMed
    1. Eur J Pharm Biopharm. 2011 Jun;78(2):208-12 - PubMed
    1. Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):11937-42 - PubMed
    1. J Pharm Sci. 2010 Dec;99(12):4812-29 - PubMed
    1. Nat Methods. 2010 Mar;7(3):237-42 - PubMed

Publication types

MeSH terms

LinkOut - more resources